sorbitol has been researched along with Disease Models, Animal in 82 studies
D-glucitol : The D-enantiomer of glucitol (also known as D-sorbitol).
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In addition, sorbitol levels were estimated in the cataractous lenses of the obese rats." | 7.78 | Activation of sorbitol pathway in metabolic syndrome and increased susceptibility to cataract in Wistar-Obese rats. ( Giridharan, NV; Reddy, GB; Reddy, PY, 2012) |
| "To study the possible causes of sorbitol (S)-based diarrhea and its mechanism of reduction by rice gruel (RG) in cecectomized rats." | 7.73 | Sorbitol-based osmotic diarrhea: possible causes and mechanism of prevention investigated in rats. ( Islam, MS; Sakaguchi, E, 2006) |
| "Lenses exposed to high concentrations of xylose in organ culture produce xylitol, and they lose transparency and exhibit other changes characteristic of cataracts." | 7.70 | Effects of xylose on monkey lenses in organ culture: a model for study of sugar cataracts in a primate. ( Blum, PS; Jernigan, HM; Liu, Y; Merola, LO; Stimbert, CD; Zigler, JS, 1998) |
| "The effect of pyruvate on the progress of galactose cataract has been studied." | 7.68 | Prevention of galactose cataract by pyruvate. ( Devamanoharan, PS; Henein, M; Ramachandran, S; Varma, SD, 1992) |
| " However, low peroral bioavailability is a major limiting factor for the success of clinical utilization of curcumin." | 5.39 | Efficacy of biodegradable curcumin nanoparticles in delaying cataract in diabetic rat model. ( Balakrishna, N; Grama, CN; Kumar, MN; Patil, MA; Raghu, G; Reddy, GB; Suryanarayana, P, 2013) |
| "Atherosclerosis is a major cause of death in the Western World." | 5.39 | Ozone oxidative preconditioning prevents atherosclerosis development in New Zealand White rabbits. ( Delgado-Roche, L; Martínez-Sánchez, G; Re, L, 2013) |
| "SGL5213 and miglitol improved obesity, liver dysfunction, insulin resistance, and the NAFLD severity." | 4.02 | Protective effect of SGL5213, a potent intestinal sodium-glucose cotransporter 1 inhibitor, in nonalcoholic fatty liver disease in mice. ( Honda, Y; Imajo, K; Iwaki, M; Kessoku, T; Kobayashi, T; Nagashima, Y; Nakajima, A; Nogami, A; Ogawa, Y; Ozaki, A; Saito, S; Tomeno, W; Yoneda, M, 2021) |
| "Renal anemia was induced by treatment with adenine (200 or 600 mg/kg/day, orally for 10 days) in non-diabetic Wistar-Kyoto or Wistar rats, respectively." | 3.96 | Failure to confirm a sodium-glucose cotransporter 2 inhibitor-induced hematopoietic effect in non-diabetic rats with renal anemia. ( Hitomi, H; Kittikulsuth, W; Kobara, H; Konishi, Y; Masaki, T; Morikawa, T; Nakano, D; Nishiyama, A; Osafune, K; Yamazaki, D, 2020) |
| "The results of experimental investigation of regenerative process peculiarities in the intestinal wall after its mechanical lower impassability (ileus) in terms of 1, 3, 7 and 14 days without medicinal correction and together with using the solutions of sorbitol and L-arginine (tivortin) in combination with application of the intratissue electrophoresis with a constant current density 0." | 3.81 | [Dynamics of reparative processes in wall of a small bowel loop after elimination of its acute mechanical ileus, depending on duration of incarceration]. ( Kolomoyets, M, 2015) |
| " In addition, sorbitol levels were estimated in the cataractous lenses of the obese rats." | 3.78 | Activation of sorbitol pathway in metabolic syndrome and increased susceptibility to cataract in Wistar-Obese rats. ( Giridharan, NV; Reddy, GB; Reddy, PY, 2012) |
| "To study the possible causes of sorbitol (S)-based diarrhea and its mechanism of reduction by rice gruel (RG) in cecectomized rats." | 3.73 | Sorbitol-based osmotic diarrhea: possible causes and mechanism of prevention investigated in rats. ( Islam, MS; Sakaguchi, E, 2006) |
| "Lenses exposed to high concentrations of xylose in organ culture produce xylitol, and they lose transparency and exhibit other changes characteristic of cataracts." | 3.70 | Effects of xylose on monkey lenses in organ culture: a model for study of sugar cataracts in a primate. ( Blum, PS; Jernigan, HM; Liu, Y; Merola, LO; Stimbert, CD; Zigler, JS, 1998) |
| "Aldose reductase catalyzes the NADPH-linked reduction of hexoses to their respective sugar-alcohols, which are involved in the pathogenesis of "sugar-cataracts"." | 3.68 | Effects of G-6-PD deficiency, experimentally induced or genetically transmitted, on the sorbitol pathway activity. In vitro and in vivo studies. ( Alvarez, A; Chávez, M; Chávez-Anaya, E; Medina, C; Medina, MD; Mendoza, R; Ramírez, MG; Sáenz, G; Vaca, G; Vargas, M, 1992) |
| "The effect of pyruvate on the progress of galactose cataract has been studied." | 3.68 | Prevention of galactose cataract by pyruvate. ( Devamanoharan, PS; Henein, M; Ramachandran, S; Varma, SD, 1992) |
| "Diabetic retinopathy is the most common microvascular complication of diabetes and the most severe of diabetic ocular complications." | 2.47 | Aldose reductase / polyol inhibitors for diabetic retinopathy. ( Kador, PF; Obrosova, IG, 2011) |
| "Glaucoma is a leading cause of blindness." | 2.47 | Clinical and experimental links between diabetes and glaucoma. ( Bui, BV; Vingrys, AJ; Wong, VH, 2011) |
| "Diabetic retinopathy is similarly related to sorbitol accumulation and may be prevented or reversed by inhibition of aldose reductase." | 2.37 | NIH conference. Aldose reductase and complications of diabetes. ( Cobo, LM; Cogan, DG; Datilis, MB; Kador, PF; Kinoshita, JH; Kupfer, C; Robison, G, 1984) |
| " A novel polytherapeutic proof-of-principle approach using PXT3003, a low-dose combination of baclofen, naltrexone and sorbitol, slowed disease progression after long-term dosing in adult Pmp22 transgenic rats, a known animal model of CMT1A." | 1.51 | Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A). ( Adam, J; Cohen, D; Ewers, D; Hajj, R; Kungl, T; Mroczek, M; Nabirotchkin, S; Nave, KA; Prukop, T; Sereda, MW; Stenzel, J; Wernick, S, 2019) |
| "Modafinil is a wake-promoting drug and has been approved for the treatment of excessive daytime sleepiness in narcolepsy and obstructive sleep apnea." | 1.39 | Differential effects of modafinil on memory in naïve and memory-impaired rats. ( Busato, SB; D'avila Portal, BC; Garcia, VA; Piazza, FC; Schröder, N; Souza de Freitas, B, 2013) |
| " However, low peroral bioavailability is a major limiting factor for the success of clinical utilization of curcumin." | 1.39 | Efficacy of biodegradable curcumin nanoparticles in delaying cataract in diabetic rat model. ( Balakrishna, N; Grama, CN; Kumar, MN; Patil, MA; Raghu, G; Reddy, GB; Suryanarayana, P, 2013) |
| "Atherosclerosis is a major cause of death in the Western World." | 1.39 | Ozone oxidative preconditioning prevents atherosclerosis development in New Zealand White rabbits. ( Delgado-Roche, L; Martínez-Sánchez, G; Re, L, 2013) |
| " However, DDB therapeutic effectiveness is restricted by its low oral bioavailability that arises from its poor solubility and dissolution." | 1.38 | Novel diphenyl dimethyl bicarboxylate provesicular powders with enhanced hepatocurative activity: preparation, optimization, in vitro/in vivo evaluation. ( Abdelbary, GA; Aburahma, MH, 2012) |
| " Owing to aldose reductase pharmacophore requirements for an acidic proton, most aldose reductase inhibitors contain an acetic acid moiety, ionized at physiological pH, resulting in poor bioavailability of the drugs." | 1.37 | (2-Benzyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-8-yl)-acetic acid: an aldose reductase inhibitor and antioxidant of zwitterionic nature. ( Juskova, M; Milackova, I; Snirc, V; Stefek, M; Triantos, N; Tsantili-Kakoulidou, A, 2011) |
| " These data suggest that increasing NO bioavailability by L-arginine corrects the major biochemical abnormalities of diabetes." | 1.35 | L-Arginine prevents metabolic effects of high glucose in diabetic mice. ( Bhatnagar, A; Kaiserova, K; Ramana, KV; Srivastava, SK; West, MB, 2008) |
| "Inositol was diminished in diabetes to 0." | 1.28 | Myocardial inositol and sodium in diabetes. ( Beyer-Mears, A; Fusilli, LD; Regan, TJ; Torres, R, 1992) |
| " High dietary concentrations of lactose give rise to a similar spectrum of effects when given in excessive dosage to laboratory rats." | 1.27 | Perspectives in carbohydrate toxicology with special reference to carcinogenicity. ( Roe, FJ, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 26 (31.71) | 18.7374 |
| 1990's | 13 (15.85) | 18.2507 |
| 2000's | 17 (20.73) | 29.6817 |
| 2010's | 21 (25.61) | 24.3611 |
| 2020's | 5 (6.10) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Mori, Y | 1 |
| Terasaki, M | 1 |
| Hiromura, M | 1 |
| Saito, T | 1 |
| Kushima, H | 1 |
| Koshibu, M | 1 |
| Osaka, N | 1 |
| Ohara, M | 1 |
| Fukui, T | 1 |
| Ohtaki, H | 1 |
| Tsutomu, H | 1 |
| Yamagishi, SI | 1 |
| Yamazaki, D | 1 |
| Konishi, Y | 1 |
| Morikawa, T | 1 |
| Kobara, H | 2 |
| Masaki, T | 2 |
| Hitomi, H | 2 |
| Osafune, K | 1 |
| Nakano, D | 2 |
| Kittikulsuth, W | 1 |
| Nishiyama, A | 2 |
| Wang, M | 1 |
| Chen, WY | 1 |
| Zhang, J | 1 |
| Gobejishvili, L | 1 |
| Barve, SS | 1 |
| McClain, CJ | 1 |
| Joshi-Barve, S | 1 |
| Vo, MC | 1 |
| Ahn, SY | 1 |
| Chu, TH | 1 |
| Uthaman, S | 1 |
| Pillarisetti, S | 1 |
| Uong, TNT | 1 |
| Lakshmi, TJ | 1 |
| Kim, M | 1 |
| Song, GY | 1 |
| Jung, SH | 1 |
| Yang, DH | 1 |
| Ahn, JS | 1 |
| Kim, HJ | 1 |
| Park, IK | 1 |
| Lee, JJ | 1 |
| Honda, Y | 1 |
| Ozaki, A | 1 |
| Iwaki, M | 1 |
| Kobayashi, T | 1 |
| Nogami, A | 1 |
| Kessoku, T | 1 |
| Ogawa, Y | 1 |
| Tomeno, W | 1 |
| Imajo, K | 1 |
| Yoneda, M | 1 |
| Saito, S | 1 |
| Nagashima, Y | 1 |
| Nakajima, A | 1 |
| Werner, RA | 1 |
| Wakabayashi, H | 1 |
| Chen, X | 1 |
| Hirano, M | 1 |
| Shinaji, T | 1 |
| Lapa, C | 1 |
| Rowe, SP | 1 |
| Javadi, MS | 1 |
| Higuchi, T | 1 |
| Takahashi, K | 1 |
| Nakamura, A | 1 |
| Miyoshi, H | 1 |
| Nomoto, H | 1 |
| Kitao, N | 1 |
| Omori, K | 1 |
| Yamamoto, K | 1 |
| Cho, KY | 1 |
| Terauchi, Y | 1 |
| Atsumi, T | 1 |
| Zhang, Y | 2 |
| Guan, Y | 1 |
| Uemura, A | 1 |
| Sugaya, T | 1 |
| Prukop, T | 1 |
| Stenzel, J | 1 |
| Wernick, S | 1 |
| Kungl, T | 1 |
| Mroczek, M | 1 |
| Adam, J | 1 |
| Ewers, D | 1 |
| Nabirotchkin, S | 2 |
| Nave, KA | 2 |
| Hajj, R | 2 |
| Cohen, D | 2 |
| Sereda, MW | 2 |
| Garcia, VA | 1 |
| Souza de Freitas, B | 1 |
| Busato, SB | 1 |
| D'avila Portal, BC | 1 |
| Piazza, FC | 1 |
| Schröder, N | 1 |
| Grama, CN | 1 |
| Suryanarayana, P | 1 |
| Patil, MA | 1 |
| Raghu, G | 1 |
| Balakrishna, N | 1 |
| Kumar, MN | 1 |
| Reddy, GB | 2 |
| Milackova, I | 2 |
| Prnova, MS | 1 |
| Majekova, M | 1 |
| Sotnikova, R | 1 |
| Stasko, M | 1 |
| Kovacikova, L | 1 |
| Banerjee, S | 1 |
| Veverka, M | 1 |
| Stefek, M | 2 |
| Kim, YK | 1 |
| Xing, L | 1 |
| Chen, BA | 1 |
| Xu, F | 1 |
| Jiang, HL | 1 |
| Zhang, C | 1 |
| Chumakov, I | 1 |
| Milet, A | 1 |
| Cholet, N | 1 |
| Primas, G | 1 |
| Boucard, A | 1 |
| Pereira, Y | 1 |
| Graudens, E | 1 |
| Mandel, J | 1 |
| Laffaire, J | 1 |
| Foucquier, J | 1 |
| Glibert, F | 1 |
| Bertrand, V | 1 |
| Vial, E | 1 |
| Guedj, M | 1 |
| Kolomoyets, M | 1 |
| Freeman, OJ | 1 |
| Unwin, RD | 1 |
| Dowsey, AW | 1 |
| Begley, P | 1 |
| Ali, S | 1 |
| Hollywood, KA | 1 |
| Rustogi, N | 1 |
| Petersen, RS | 1 |
| Dunn, WB | 1 |
| Cooper, GJ | 1 |
| Gardiner, NJ | 1 |
| Gugliucci, A | 1 |
| Forbes, JM | 1 |
| Coughlan, MT | 1 |
| Cooper, ME | 1 |
| West, MB | 1 |
| Ramana, KV | 1 |
| Kaiserova, K | 1 |
| Srivastava, SK | 1 |
| Bhatnagar, A | 1 |
| Li, X | 1 |
| Hu, J | 1 |
| Zhang, R | 1 |
| Sun, X | 1 |
| Zhang, Q | 1 |
| Guan, X | 1 |
| Chen, J | 1 |
| Zhu, Q | 1 |
| Li, S | 1 |
| Chan, AW | 1 |
| Ho, YS | 1 |
| Chung, SK | 1 |
| Chung, SS | 1 |
| van der Hoven, B | 1 |
| van Pelt, H | 1 |
| Swart, EL | 1 |
| Bonthuis, F | 1 |
| Tilanus, HW | 1 |
| Bakker, J | 1 |
| Gommers, D | 1 |
| Obrosova, IG | 1 |
| Kador, PF | 3 |
| Wong, VH | 1 |
| Bui, BV | 1 |
| Vingrys, AJ | 1 |
| Tsantili-Kakoulidou, A | 1 |
| Juskova, M | 1 |
| Snirc, V | 1 |
| Triantos, N | 1 |
| Aburahma, MH | 1 |
| Abdelbary, GA | 1 |
| Soto, Y | 1 |
| Acosta, E | 1 |
| Delgado, L | 1 |
| Pérez, A | 1 |
| Falcón, V | 1 |
| Bécquer, MA | 1 |
| Fraga, Á | 1 |
| Brito, V | 1 |
| Álvarez, I | 1 |
| Griñán, T | 1 |
| Fernández-Marrero, Y | 1 |
| López-Requena, A | 1 |
| Noa, M | 1 |
| Fernández, E | 1 |
| Vázquez, AM | 1 |
| Reddy, PY | 1 |
| Giridharan, NV | 1 |
| Delgado-Roche, L | 1 |
| Martínez-Sánchez, G | 1 |
| Re, L | 1 |
| Yamagishi, S | 1 |
| Uehara, K | 1 |
| Otsuki, S | 1 |
| Yagihashi, S | 2 |
| Poljak-Blazi, M | 1 |
| Hrvacić, B | 1 |
| Zupanović, Z | 1 |
| Hadzija, M | 1 |
| Stanić, B | 1 |
| Polancec, D | 1 |
| Reuss, S | 1 |
| Bürger, K | 1 |
| Claus, H | 1 |
| Reinhardt, T | 1 |
| Disque-Kaiser, U | 1 |
| Depta, AL | 1 |
| David, M | 1 |
| Gervais, HW | 1 |
| Colton, SA | 1 |
| Downs, SM | 1 |
| Yokozawa, T | 1 |
| Yamabe, N | 1 |
| Cho, EJ | 1 |
| Nakagawa, T | 1 |
| Oowada, S | 1 |
| Bernobich, E | 1 |
| Cosenzi, A | 1 |
| Campa, C | 1 |
| Zennaro, C | 1 |
| Sasso, F | 1 |
| Paoletti, S | 1 |
| Bellini, G | 1 |
| Shimada, H | 1 |
| Takahashi, M | 1 |
| Shimada, A | 1 |
| Okawara, T | 1 |
| Yasutake, A | 1 |
| Imamura, Y | 1 |
| Kiyozumi, M | 1 |
| Mack, WJ | 1 |
| Mocco, J | 1 |
| Ducruet, AF | 1 |
| Laufer, I | 1 |
| King, RG | 1 |
| Guo, W | 1 |
| Pinsky, DJ | 1 |
| Connolly, ES | 1 |
| Romanovsky, D | 1 |
| Cruz, NF | 1 |
| Dienel, GA | 1 |
| Dobretsov, M | 1 |
| Islam, MS | 1 |
| Sakaguchi, E | 1 |
| Oates, PJ | 1 |
| Cogan, DG | 1 |
| Kinoshita, JH | 2 |
| Robison, G | 1 |
| Datilis, MB | 1 |
| Cobo, LM | 1 |
| Kupfer, C | 1 |
| Roe, FJ | 1 |
| Füzesi, S | 2 |
| Hársing, J | 2 |
| Jellinek, H | 2 |
| Lanza, E | 1 |
| Dionigi, R | 1 |
| Subissi, A | 1 |
| Piccinini, F | 1 |
| Friend, J | 1 |
| Kiorpes, TC | 1 |
| Thoft, RA | 1 |
| Garcia, JH | 1 |
| Conger, KA | 1 |
| Morawetz, R | 1 |
| Halsey, JH | 1 |
| Frank, RN | 1 |
| Wada, R | 1 |
| Kamijo, M | 1 |
| Nagai, K | 1 |
| Sima, AA | 2 |
| Douillet, C | 1 |
| Bost, M | 1 |
| Accominotti, M | 1 |
| Borson-Chazot, F | 1 |
| Ciavatti, M | 1 |
| Hounsom, L | 1 |
| Tomlinson, DR | 1 |
| Gupta, R | 1 |
| Gupta, S | 1 |
| Joshi, K | 1 |
| Ganguly, NK | 1 |
| Jernigan, HM | 1 |
| Zigler, JS | 1 |
| Liu, Y | 1 |
| Blum, PS | 1 |
| Merola, LO | 1 |
| Stimbert, CD | 1 |
| Toyoda, Y | 1 |
| Ito, Y | 1 |
| Tanigawa, K | 1 |
| Miwa, I | 1 |
| Kubo, E | 1 |
| Maekawa, K | 1 |
| Tanimoto, T | 1 |
| Fujisawa, S | 1 |
| Akagi, Y | 1 |
| Kleinfeldt, D | 1 |
| Dahl, D | 1 |
| Gutman, A | 1 |
| Andreus, A | 1 |
| Adler, JH | 1 |
| Vaca, G | 1 |
| Ramírez, MG | 1 |
| Vargas, M | 1 |
| Mendoza, R | 1 |
| Chávez-Anaya, E | 1 |
| Medina, MD | 1 |
| Alvarez, A | 1 |
| Medina, C | 1 |
| Sáenz, G | 1 |
| Chávez, M | 1 |
| Regan, TJ | 1 |
| Beyer-Mears, A | 1 |
| Torres, R | 1 |
| Fusilli, LD | 1 |
| Henein, M | 1 |
| Devamanoharan, PS | 1 |
| Ramachandran, S | 1 |
| Varma, SD | 1 |
| Kito, S | 1 |
| Yamamura, Y | 1 |
| Nishikawa, M | 1 |
| Yoshida, K | 1 |
| Okamoto, M | 1 |
| Kohsaka, M | 1 |
| Hod, M | 1 |
| Star, S | 1 |
| Passonneau, J | 1 |
| Unterman, TG | 1 |
| Freinkel, N | 1 |
| Greene, DA | 1 |
| Lattimer-Greene, S | 1 |
| Low, PA | 1 |
| Schmelzer, JD | 1 |
| Ward, KK | 1 |
| Yao, JK | 1 |
| Detre, Z | 1 |
| Sharpless, NE | 1 |
| Vollerthun, R | 1 |
| Lämmler, G | 2 |
| Schuster, J | 2 |
| Holcomb, GN | 1 |
| Klemm, LA | 1 |
| Dulin, WE | 1 |
| Gabbay, KH | 1 |
| Rudolph, R | 1 |
| Zahner, H | 1 |
| DeJesus, PV | 1 |
| Clements, RS | 1 |
| Winegrad, AI | 1 |
| Rowe, MI | 1 |
| Seagram, G | 1 |
| Weinberger, M | 1 |
| Birnesser, H | 1 |
| Reinauer, H | 1 |
| Hollmann, S | 1 |
| Rauen, HM | 1 |
| Schriewer, H | 1 |
| Gebauer, B | 1 |
| Abu Tair, M | 1 |
| Rüther, N | 1 |
| The, LG | 1 |
| Keppler, DO | 1 |
| Hübner, G | 1 |
| Prockop, LD | 1 |
| Bogomolova, LG | 1 |
| Suslov, VS | 1 |
| Klement, AA | 1 |
| Andrianova, IG | 1 |
| Gefen, NG | 1 |
| Katsh, S | 1 |
| Aguirre, A | 1 |
| Willson, JT | 1 |
| Katsh, GF | 1 |
| Korostovtseva, NV | 1 |
| Kal', EA | 1 |
| Chirkova, OO | 1 |
| Volkova, SD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| International, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study Assessing in Parallel Groups the Efficacy and Safety of 2 Doses of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Treated 15 Months[NCT02579759] | Phase 3 | 323 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
ONLS Therapy Response 1 was defined as the number of participants (responders) with an improvement on final ONLS Total Score of at least one point. A higher response rate indicate a better clinical condition. (NCT02579759)
Timeframe: From Baseline to Month 15
| Intervention | Number of Participants (Number) |
|---|---|
| PXT3003 Dose 1 | 16 |
| PXT3003 Dose 2 | 14 |
| Placebo | 14 |
"ONLS Therapy Response 2 was defined as the number of participants with no deterioration (responders) on final ONLS Total Score.~A higher response rate indicates a better clinical condition." (NCT02579759)
Timeframe: From Baseline to Month 15
| Intervention | Number of Participants (Number) |
|---|---|
| PXT3003 Dose 1 | 66 |
| PXT3003 Dose 2 | 42 |
| Placebo | 58 |
Safety and tolerability of PXT3003 were compared to placebo on the incidence of TEAEs leading to withdrawal of study drug. (NCT02579759)
Timeframe: The period between the patient signing the informed consent and 30 days after the end of study (i.e. completion/early discontinuation/last contact as recorded on the 'Study Completion on Early Termination' form up to 15 months)
| Intervention | participants (Number) | |
|---|---|---|
| Any TEAE leading to drug withdrawal | Any related TEAE leading to drug withdrawal | |
| Placebo | 6 | 2 |
| PXT3003 Dose 1 | 6 | 3 |
| PXT3003 Dose 2 | 6 | 2 |
Safety and tolerability of PXT3003 were compared to placebo on the incidence of serious adverse events (SAEs). (NCT02579759)
Timeframe: The period between the patient signing the informed consent and 30 days after the end of study (i.e. completion/early discontinuation/last contact as recorded on the 'Study Completion on Early Termination' form up to 15 months).
| Intervention | participants (Number) | ||
|---|---|---|---|
| Any serious TEAE | Any related serious TEAE | Any serious TEAE leading to drug withdrawal | |
| Placebo | 5 | 0 | 0 |
| PXT3003 Dose 1 | 10 | 0 | 1 |
| PXT3003 Dose 2 | 3 | 0 | 0 |
"This outcome measure is the mean of the available 10MWT values at month 12 and month 15.~The 10MWT is a simple to administer, standardized, reliable and valid evaluation of functional exercise capacity and gait that has been used to evaluate neurologic disorders and CMT patients.~Lower Time to Walk 10 Meters values indicate a better clinical condition.~Reported values are the values at Baseline (Base) and the average of the available values at Month 12 and Month 15 (Fin)." (NCT02579759)
Timeframe: From Baseline to Month 15
| Intervention | Seconds (s) (Mean) | |
|---|---|---|
| Base | Fin | |
| Placebo | 7.28 | 6.91 |
| PXT3003 Dose 1 | 6.93 | 6.47 |
| PXT3003 Dose 2 | 7.14 | 6.52 |
"This outcome measure is the mean of the available CMTNS-v2 Examination Score values at month 12 and month 15.~The CMTNS-v2 is a specific scale designed to assess severity of impairment in CMT disease. It is a 36-point scale based on nine items to quantify impairment (sensory symptoms, pin sensibility, vibration and arm and leg strength), activity limitations (motor symptoms arms and legs) and electrophysiological function (amplitudes of ulnar CMAP and SNAP). The CMTNS-v2 goes from 0 (no impairment) to 36 (maximum impairment) whom each sub-items goes from 0 to 4.~The CMTES-v2 is summed of item 1 to 7 of the CMTNS-v2 (limited to impairment items and excluding electrophysiological items). It is a 28-point score: 0 (no impairment) to 28 (maximum impairment).~Lower CMTES-v2 values indicate a better clinical condition.~Reported values are the values at Baseline (Base) and the average of the available values at Month 12 and Month 15 (Fin)." (NCT02579759)
Timeframe: From Baseline to Month 15
| Intervention | Scores on the CMTES-v2 (Mean) | |
|---|---|---|
| Base | Fin | |
| Placebo | 9.51 | 9.02 |
| PXT3003 Dose 1 | 9.49 | 9.01 |
| PXT3003 Dose 2 | 8.78 | 8.24 |
"This outcome measure is the mean of the available CMTNS-v2 Sensory Score values at month 12 and month 15.~The CMTNS-v2 is a specific scale designed to assess severity of impairment in CMT disease. It is a 36-point scale based on nine items to quantify impairment (sensory symptoms, pin sensibility, vibration and arm and leg strength), activity limitations (motor symptoms arms and legs) and electrophysiological function (amplitudes of ulnar CMAP and SNAP). The CMTNS-v2 goes from 0 (no impairment) to 36 (maximum impairment) whom each sub-items goes from 0 to 4.~The CMTNS-v2 Sensory score is summed of items 1+4+5 of CMTNS-v2 (Sensory symptoms, Pinprick sensibility and Vibration). It is a 12-point score: 0 (no impairment) to 12 (maximum impairment).~Lower CMTNS-v2 Sensory Score values indicate a better clinical condition.~Reported values are the values at Baseline (Base) and the average of the available values at Month 12 and Month 15 (Fin)." (NCT02579759)
Timeframe: From Baseline to Month 15
| Intervention | Scores on the CMTNS-v2 Sensory Score (Mean) | |
|---|---|---|
| Base | Fin | |
| Placebo | 4.97 | 4.68 |
| PXT3003 Dose 1 | 5.00 | 4.55 |
| PXT3003 Dose 2 | 4.47 | 4.23 |
"This outcome measure is the mean of the available CMTNS-v2 Sensory Symptoms values at month 12 and month 15.~The CMTNS-v2 is a specific scale designed to assess severity of impairment in CMT disease. It is a 36-point scale based on nine items to quantify impairment (sensory symptoms, pin sensibility, vibration and arm and leg strength), activity limitations (motor symptoms arms and legs) and electrophysiological function (amplitudes of ulnar CMAP and SNAP). The CMTNS-v2 goes from 0 (no impairment) to 36 (maximum impairment) whom each sub-items goes from 0 to 4.~The CMTNS-v2 Sensory Symptoms is the first item of the CMTNS-v2. It is a 4-point score: 0 (no impairment) to 4 (maximum impairment).~Lower CMTNS-v2 Sensory Symptoms values indicate a better clinical condition.~Reported values are the values at Baseline (Base) and the average of the available values at Month 12 and Month 15 (Fin)." (NCT02579759)
Timeframe: From Baseline to Month 15
| Intervention | Scores on the CMTNS-v2 Sensory Symptoms (Mean) | |
|---|---|---|
| Base | Fin | |
| Placebo | 1.09 | 1.21 |
| PXT3003 Dose 1 | 1.26 | 1.18 |
| PXT3003 Dose 2 | 0.96 | 0.93 |
"This outcome measure is the mean of the available 9-HPT values at month 12 and month 15.~The Nine-Hole Peg Test (9HPT) is a simple timed test of fine motor coordination of extremitied in the upper limbs. It measures the time needed by the patient to insert 9 pegs in nine holes and to remove them (normal required time 18 seconds).~Lower 9HPT values indicate a better clinical condition.~Reported values are the values at Baseline (Base) and the average of the available values at Month 12 and Month 15 (Fin)." (NCT02579759)
Timeframe: From Baseline to Month 15
| Intervention | Seconds (s) (Mean) | |
|---|---|---|
| Base | Fin | |
| Placebo | 25.18 | 24.41 |
| PXT3003 Dose 1 | 25.62 | 23.85 |
| PXT3003 Dose 2 | 27.33 | 25.67 |
"Safety selection was to include all randomized patients that have received at least one dose of study treatment.~Safety and tolerability of PXT3003 were compared to placebo on the incidence of treatment-emergent adverse events (TEAEs); they were evaluated by type/nature, severity/intensity, seriousness, and relationship to study drug." (NCT02579759)
Timeframe: The period between the patient signing the informed consent and 30 days after the end of study (i.e. completion/early discontinuation/last contact as recorded on the 'Study Completion on Early Termination' form up to 15 months)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Any TEAE | Any related TEAE | Any moderately severe or severe related TEAE | |
| Placebo | 83 | 34 | 10 |
| PXT3003 Dose 1 | 89 | 39 | 8 |
| PXT3003 Dose 2 | 87 | 38 | 5 |
"The primary efficacy variable used in the main analysis is the mean of the available ONLS values at month 12 and month 15.~The ONLS is a disability scale that was derived and improved from the Overall Disability Sum Score (ODSS) to measure limitations in the everyday activities of the upper limbs (rated on 5 points) and the lower limbs (rated on 7 points). The total score is a 12-point scale: 0 (no disability) to 12 (maximum disability). Lower values in the ONLS indicate a better clinical condition.~Reported values are the values at Baseline (Base) and the average of the available values at Month 12 and Month 15 (Fin)." (NCT02579759)
Timeframe: From Baseline to Month 15
| Intervention | Scores on the ONLS (Mean) | |
|---|---|---|
| Base | Fin | |
| Placebo | 3.23 | 3.36 |
| PXT3003 Dose 1 | 3.33 | 3.25 |
| PXT3003 Dose 2 | 3.05 | 2.82 |
"Plasma concentration of PXT3003 components were measured at trough (prior to dose) and peak (90 minutes post dose).~The mean plasma values of the baseline correspond to half of the administered dose." (NCT02579759)
Timeframe: At Month 12 and Month 15
| Intervention | pg/mL (Mean) | |||
|---|---|---|---|---|
| At trough, at Month 12 | At trough, at Month 15 | At 90 min after drug intake, at Month 12 | At 90 min after drug intake, at Month 15 | |
| PXT3003 Dose 1 | 290.1 | 260.4 | 632.5 | 586.4 |
| PXT3003 Dose 2 | 526.4 | 352.3 | 1257.1 | 1450.9 |
"Plasma concentration of PXT3003 components were measured at trough (prior to dose) and 90 minutes after drug intake.~The mean plasma values of the baseline correspond to half of the administered dose." (NCT02579759)
Timeframe: At Month 12 and Month 15
| Intervention | pg/mL (Mean) | |||
|---|---|---|---|---|
| At trough, at Month 12 | At trough, at Month 15 | At 90 min after drug intake, at Month 12 | At 90 min after drug intake, at Month 15 | |
| PXT3003 Dose 1 | 13739.3 | 9009.7 | 52201.6 | 47021.1 |
| PXT3003 Dose 2 | 11651.9 | 8686.6 | 90238.7 | 105825.4 |
"Plasma concentration of PXT3003 components were measured at trough (prior to dose) and 90 minutes after drug intake.~The mean plasma values of the baseline correspond to half of the administered dose." (NCT02579759)
Timeframe: At Month 12 and month 15
| Intervention | pg/mL (Mean) | |||
|---|---|---|---|---|
| At trough, at Month 12 | At trough, at Month 15 | At 90 min after drug intake, at Month 12 | At 90 min after drug intake, at Month 15 | |
| PXT3003 Dose 1 | 33.0 | 31.8 | 63.0 | 55.0 |
| PXT3003 Dose 2 | 42.0 | 30.0 | 107.5 | 130.9 |
12 reviews available for sorbitol and Disease Models, Animal
| Article | Year |
|---|---|
Formation of Fructose-Mediated Advanced Glycation End Products and Their Roles in Metabolic and Inflammatory Diseases.
Topics: Adenosine Triphosphate; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Fructose; Glycat | 2017 |
Oxidative stress as a major culprit in kidney disease in diabetes.
Topics: Animals; Cytosol; Diabetic Nephropathies; Disease Models, Animal; Energy Metabolism; Glucose; Glucos | 2008 |
Aldose reductase / polyol inhibitors for diabetic retinopathy.
Topics: Aldehyde Reductase; Animals; Clinical Trials as Topic; Diabetic Retinopathy; Disease Models, Animal; | 2011 |
Clinical and experimental links between diabetes and glaucoma.
Topics: Animals; Apoptosis; Cell Death; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Di | 2011 |
Aldose reductase, still a compelling target for diabetic neuropathy.
Topics: Aldehyde Reductase; Animals; Controlled Clinical Trials as Topic; Diabetic Neuropathies; Disease Mod | 2008 |
NIH conference. Aldose reductase and complications of diabetes.
Topics: Aldehyde Reductase; Animals; Axonal Transport; Cataract; Corneal Diseases; Diabetic Neuropathies; Di | 1984 |
Metabolic alterations of peripheral nerve in diabetes.
Topics: Aldehyde Reductase; Animals; Diabetic Neuropathies; Disease Models, Animal; Enzyme Inhibitors; Fatty | 1996 |
Does neuropathy develop in animal models?
Topics: Animals; Axotomy; Biological Transport; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Dise | 1997 |
[Diabetic neuropathy--a review of pathological studies].
Topics: Adolescent; Adult; Aged; Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Disease Mo | 1991 |
Pathogenesis of diabetic neuropathy: role of altered phosphoinositide metabolism.
Topics: Animals; Diabetic Neuropathies; Disease Models, Animal; Humans; Inositol; Neural Conduction; Periphe | 1989 |
[The role of transmural permeability disorders in the pathomechanism of arteriosclerosis. II. Model experiments].
Topics: Animals; Aorta, Thoracic; Arteriosclerosis; Capillary Permeability; Cell Membrane Permeability; Coro | 1985 |
Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications.
Topics: Aldehyde Reductase; Animals; Binding Sites; Blood Glucose; Cataract; Chemical Phenomena; Chemistry; | 1985 |
70 other studies available for sorbitol and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Luseogliflozin attenuates neointimal hyperplasia after wire injury in high-fat diet-fed mice via inhibition of perivascular adipose tissue remodeling.
Topics: Adiponectin; Adipose Tissue; Adiposity; Animals; Diet, High-Fat; Disease Models, Animal; Femoral Art | 2019 |
Failure to confirm a sodium-glucose cotransporter 2 inhibitor-induced hematopoietic effect in non-diabetic rats with renal anemia.
Topics: Adenine; Anemia; Animals; Disease Models, Animal; Erythropoietin; Hematocrit; Hematopoietic Stem Cel | 2020 |
Elevated Fructose and Uric Acid Through Aldose Reductase Contribute to Experimental and Human Alcoholic Liver Disease.
Topics: Adult; Aldehyde Reductase; Animals; Apoptosis; Case-Control Studies; Cohort Studies; Disease Models, | 2020 |
A combination of immunoadjuvant nanocomplexes and dendritic cell vaccines in the presence of immune checkpoint blockade for effective cancer immunotherapy.
Topics: Adjuvants, Immunologic; Animals; Cancer Vaccines; Colonic Neoplasms; Combined Modality Therapy; Dend | 2021 |
Protective effect of SGL5213, a potent intestinal sodium-glucose cotransporter 1 inhibitor, in nonalcoholic fatty liver disease in mice.
Topics: 1-Deoxynojirimycin; Animals; Chronic Disease; Diet, High-Fat; Dietary Sucrose; Disease Models, Anima | 2021 |
Functional Renal Imaging with 2-Deoxy-2-
Topics: Animals; Disease Models, Animal; Fluorine Radioisotopes; Glomerular Filtration Rate; Kidney; Kidney | 2018 |
Effect of the sodium-glucose cotransporter 2 inhibitor luseogliflozin on pancreatic beta cell mass in db/db mice of different ages.
Topics: Age Factors; Animals; Cyclin D2; Diabetes Mellitus, Type 2; Disease Models, Animal; Homeodomain Prot | 2018 |
A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice.
Topics: Acute Kidney Injury; Angiogenesis Inhibitors; Animals; Blood Glucose; Capillaries; Disease Models, A | 2018 |
Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A).
Topics: Animals; Axons; Baclofen; Charcot-Marie-Tooth Disease; Demyelinating Diseases; Disease Models, Anima | 2019 |
Differential effects of modafinil on memory in naïve and memory-impaired rats.
Topics: Analysis of Variance; Animals; Animals, Newborn; Avoidance Learning; Benzhydryl Compounds; Disease M | 2013 |
Efficacy of biodegradable curcumin nanoparticles in delaying cataract in diabetic rat model.
Topics: Aldehyde Reductase; Animals; Antioxidants; Biocompatible Materials; Biodegradation, Environmental; B | 2013 |
2-Chloro-1,4-naphthoquinone derivative of quercetin as an inhibitor of aldose reductase and anti-inflammatory agent.
Topics: Aldehyde Reductase; Animals; Anti-Inflammatory Agents; Colitis; Disease Models, Animal; Erythrocytes | 2015 |
Aerosol delivery of programmed cell death protein 4 using polysorbitol-based gene delivery system for lung cancer therapy.
Topics: Aerosols; Animals; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Survival; Disease Models, A | 2014 |
Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy.
Topics: Animals; Axons; Baclofen; Charcot-Marie-Tooth Disease; Coculture Techniques; Disease Models, Animal; | 2014 |
[Dynamics of reparative processes in wall of a small bowel loop after elimination of its acute mechanical ileus, depending on duration of incarceration].
Topics: Animals; Arginine; Disease Models, Animal; Electrochemotherapy; Ileus; Intestine, Small; Rats; Recov | 2015 |
Metabolic Dysfunction Is Restricted to the Sciatic Nerve in Experimental Diabetic Neuropathy.
Topics: Animals; Carnitine; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Disease Models, Animal; | 2016 |
L-Arginine prevents metabolic effects of high glucose in diabetic mice.
Topics: Aldehyde Reductase; Animals; Aortitis; Arginine; Diabetes Mellitus, Experimental; Diabetes Mellitus, | 2008 |
Urocortin ameliorates diabetic nephropathy in obese db/db mice.
Topics: Animals; Blood Glucose; Blood Urea Nitrogen; Body Weight; Cell Line; Connective Tissue Growth Factor | 2008 |
Synergistic effect of osmotic and oxidative stress in slow-developing cataract formation.
Topics: Aging; Aldehyde Reductase; Animals; Antioxidants; Cataract; Diabetes Mellitus, Experimental; Disease | 2008 |
Noninvasive functional liver blood flow measurement: comparison between bolus dose and steady-state clearance of sorbitol in a small-rodent model.
Topics: Animals; Disease Models, Animal; Injections, Intravenous; Lipopolysaccharides; Liver; Liver Circulat | 2010 |
(2-Benzyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-8-yl)-acetic acid: an aldose reductase inhibitor and antioxidant of zwitterionic nature.
Topics: Acetates; Aldehyde Reductase; Animals; Antioxidants; Diabetes Mellitus, Experimental; Disease Models | 2011 |
Novel diphenyl dimethyl bicarboxylate provesicular powders with enhanced hepatocurative activity: preparation, optimization, in vitro/in vivo evaluation.
Topics: Administration, Oral; Alanine Transaminase; Animals; Aspartate Aminotransferases; Biomarkers; Calori | 2012 |
Antiatherosclerotic effect of an antibody that binds to extracellular matrix glycosaminoglycans.
Topics: Animals; Antibodies, Monoclonal; Antibody Specificity; Atherosclerosis; Biological Transport; Cell L | 2012 |
Activation of sorbitol pathway in metabolic syndrome and increased susceptibility to cataract in Wistar-Obese rats.
Topics: Age Factors; Animals; Antioxidants; Cataract; Disease Models, Animal; Disease Susceptibility; Eye Pr | 2012 |
Ozone oxidative preconditioning prevents atherosclerosis development in New Zealand White rabbits.
Topics: Animals; Antioxidants; Aorta; Atherosclerosis; Disease Models, Animal; Drug Combinations; Lipids; Ma | 2013 |
Differential influence of increased polyol pathway on protein kinase C expressions between endoneurial and epineurial tissues in diabetic mice.
Topics: Animals; Blotting, Western; Diabetes Mellitus, Experimental; Disease Models, Animal; Female; Fructos | 2003 |
Differing effects of two iron compounds on experimental arthritis, TNF-alpha levels and immune response in mice.
Topics: Animals; Arthritis, Experimental; Autoimmunity; Cell Division; Cells, Cultured; Citric Acid; Disease | 2003 |
Acute moderate hyponatraemia and its rapid correction: effects on striatal and pontine ultrastructure in an animal model of the TURP syndrome.
Topics: Animals; Astrocytes; Cell Count; Corpus Striatum; Crystalloid Solutions; Disease Models, Animal; Hyp | 2004 |
Potential role for the sorbitol pathway in the meiotic dysfunction exhibited by oocytes from diabetic mice.
Topics: Aldehyde Reductase; Analysis of Variance; Animals; Carbon Isotopes; Cells, Cultured; Crosses, Geneti | 2004 |
A study on the effects to diabetic nephropathy of Hachimi-jio-gan in rats.
Topics: Administration, Oral; Animals; Blood Glucose; Body Weight; Creatinine; Diabetes Mellitus, Experiment | 2004 |
Antihypertensive treatment and renal damage: amlodipine exerts protective effect through the polyol pathway.
Topics: Administration, Oral; Amlodipine; Animals; Blood Glucose; Blood Pressure; Body Weight; Collagen Type | 2004 |
Protection from spontaneous hepatocellular damage by N-benzyl-d-glucamine dithiocarbamate in Long-Evans Cinnamon rats, an animal model of Wilson's disease.
Topics: Animals; Body Weight; Chelating Agents; Copper; Disease Models, Animal; Dose-Response Relationship, | 2005 |
A cerebroprotective dose of intravenous citrate/sorbitol-stabilized dehydroascorbic acid is correlated with increased cerebral ascorbic acid and inhibited lipid peroxidation after murine reperfused stroke.
Topics: Animals; Antioxidants; Ascorbic Acid; Brain Ischemia; Cerebral Cortex; Cerebral Infarction; Citric A | 2006 |
Mechanical hyperalgesia correlates with insulin deficiency in normoglycemic streptozotocin-treated rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Disease Models, Anim | 2006 |
Sorbitol-based osmotic diarrhea: possible causes and mechanism of prevention investigated in rats.
Topics: Animal Feed; Animals; Cathartics; Diarrhea; Disease Models, Animal; Malabsorption Syndromes; Male; O | 2006 |
Perspectives in carbohydrate toxicology with special reference to carcinogenicity.
Topics: Animal Nutritional Physiological Phenomena; Animals; Carcinogens; Disease Models, Animal; Female; Hu | 1984 |
Characteristic features of the smooth muscle cell migration in vascular wall injury.
Topics: Animals; Aorta; Arteriosclerosis; Cell Movement; Disease Models, Animal; Drug Combinations; Emulsion | 1982 |
Effects of experimental atherosclerosis on cerebral blood flow in rabbits. Reversal by sorbinicate.
Topics: Animals; Arteries; Arteriosclerosis; Blood Pressure; Cerebrovascular Circulation; Cholesterol; Diet, | 1982 |
Diabetes mellitus and the rabbit corneal epithelium.
Topics: Animals; Cornea; Corneal Diseases; Corneal Injuries; Diabetes Mellitus, Experimental; Disease Models | 1981 |
[A new model for arteriosclerosis. Electron microscopic study of the reaction of the arterial wall following lipofundin-S administration].
Topics: Animals; Arteries; Arteriosclerosis; Disease Models, Animal; Drug Combinations; Injections, Intraven | 1981 |
Postischemic brain edema: quantitation and evolution.
Topics: Blood-Brain Barrier; Body Fluid Compartments; Brain Edema; Brain Ischemia; Caudate Nucleus; Cerebral | 1980 |
The galactosemic dog. A valid model for both early and late stages of diabetic retinopathy.
Topics: Animals; Diabetic Retinopathy; Disease Models, Animal; Dogs; Galactose; Galactosemias; Optic Disk; R | 1995 |
Peripheral neuropathy in the WBN/Kob rat with chronic pancreatitis and spontaneous diabetes.
Topics: Action Potentials; Animals; Axons; Diabetes Complications; Diabetes Mellitus; Diabetic Neuropathies; | 1993 |
In vitro and in vivo effects of selenium and selenium with vitamin E on platelet functions in diabetic rats relationship to platelet sorbitol and fatty acid distribution.
Topics: Adenosine Diphosphate; Animals; Blood Platelets; Chromatography, High Pressure Liquid; Diabetes Mell | 1996 |
Role of iron and iron chelation therapy in oxygen free radical mediated tissue injury in an ascending mouse model of chronic pyelonephritis.
Topics: Animals; Chelation Therapy; Chronic Disease; Citric Acid; Deferoxamine; Disease Models, Animal; Drug | 1997 |
Effects of xylose on monkey lenses in organ culture: a model for study of sugar cataracts in a primate.
Topics: Animals; Cataract; Disease Models, Animal; Galactitol; Galactose; Glucose; Lens, Crystalline; Macaca | 1998 |
Impairment of glucokinase translocation in cultured hepatocytes from OLETF and GK rats, animal models of type 2 diabetes.
Topics: Animals; Cell Nucleus; Cells, Cultured; Cytoplasm; Diabetes Mellitus, Type 2; Disease Models, Animal | 2000 |
Biochemical and morphological changes during development of sugar cataract in Otsuka Long-Evans Tokushima fatty (OLETF) rat.
Topics: Aldehyde Reductase; Animals; Cataract; Diabetes Mellitus, Type 2; Disease Models, Animal; L-Iditol 2 | 2001 |
[Animal experiments on the influence of sarbitol on the damaged internal ear (author's transl)].
Topics: Action Potentials; Animals; Disease Models, Animal; Ear, Inner; Hearing Disorders; Rabbits; Sorbitol | 1976 |
Hyperinsulinemia, insulin resistance and cataract formation in sand rats.
Topics: Adipose Tissue; Animals; Cataract; Diet; Disease Models, Animal; Galactitol; Glucose; Hyperglycemia; | 1975 |
Effects of G-6-PD deficiency, experimentally induced or genetically transmitted, on the sorbitol pathway activity. In vitro and in vivo studies.
Topics: Acetaminophen; Adolescent; Adult; Aged; Aged, 80 and over; Aldehyde Reductase; Animals; Black People | 1992 |
Myocardial inositol and sodium in diabetes.
Topics: Animals; Biopsy; Body Fluid Compartments; Chromatography, Gas; Diabetes Mellitus, Experimental; Dise | 1992 |
Prevention of galactose cataract by pyruvate.
Topics: Adenosine Triphosphate; Animals; Cataract; Crystallins; Diet; Disease Models, Animal; Galactitol; Ga | 1992 |
Studies on WE-3681, a novel aldose reductase inhibitor. III. Effects of WF-3681 and its derivatives on sorbitol accumulation in diabetic rats.
Topics: Aldehyde Reductase; Animals; Diabetes Mellitus, Experimental; Disease Models, Animal; Furans; Male; | 1990 |
Glucose-induced dysmorphogenesis in the cultured rat conceptus: prevention by supplementation with myo-inositol.
Topics: Animals; Congenital Abnormalities; Culture Media; Culture Techniques; Disease Models, Animal; Embryo | 1990 |
Experimental chronic hypoxic neuropathy: relevance to diabetic neuropathy.
Topics: Animals; Diabetic Neuropathies; Disease Models, Animal; Electrophysiology; Glycated Hemoglobin; Hexo | 1986 |
[Capillaria hepatica infection of Mastomys natalensis: alterations of enzyme activities in serum (author's transl)].
Topics: Alanine Transaminase; Alcohol Oxidoreductases; Alkaline Phosphatase; Animals; Aspartate Aminotransfe | 1974 |
The polyol pathway for glucose metabolism in tissues from normal, diabetic, and ketotic Chinese hamsters.
Topics: Animals; Blood Glucose; Cricetinae; Diabetes Mellitus; Diabetic Ketoacidosis; Disease Models, Animal | 1974 |
Role of sorbitol pathway in neuropathy.
Topics: Animals; Blood Glucose; Diabetes Mellitus; Diabetic Neuropathies; Disease Models, Animal; Fructose; | 1973 |
[Pathophysiological and toxicological aspects of Schistosoma mansoni infection in Mastomys natalensis under treatment with Hycanthone].
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Disease Models, Animal; Female; Glutamat | 1973 |
Hypermyoinositolemic polyneuropathy in rats. A possible mechanism for uremic polyneuropathy.
Topics: Animals; Blood Glucose; Blood Urea Nitrogen; Disease Models, Animal; Electric Stimulation; Evoked Po | 1974 |
Gastrografin-induced hypertonicity. The pathogenesis of a neonatal hazard.
Topics: Amino Sugars; Animals; Animals, Newborn; Diatrizoate; Disease Models, Animal; Dogs; Enema; Intestina | 1973 |
Comparative study of enzyme activities degrading sorbitol, ribitol, xylitol and gluconate in guinea pig tissues.
Topics: Adipose Tissue; Animals; Brain; Diabetes Mellitus; Diabetes Mellitus, Experimental; Disease Models, | 1973 |
[Multivariant analysis of experimental liver damage: normal parameters of the rat serum].
Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Aspartate Aminotransferases; Barbiturates; Chem | 1973 |
Liver injury induced by 2-deoxy-D-galactose.
Topics: Alcohol Oxidoreductases; Animals; Aspartate Aminotransferases; Bilirubin; Chemical and Drug Induced | 1973 |
Hyperglycemia, polyol accumulation, and increased intracranial pressure.
Topics: Animals; Brain; Brain Edema; Cerebrospinal Fluid Proteins; Diabetic Ketoacidosis; Disease Models, An | 1971 |
[Lyophilized sorbitol as a therapeutic preparation].
Topics: Adult; Animals; Disease Models, Animal; Diuretics; Dogs; Freeze Drying; Gangrene; Gastrointestinal M | 1971 |
Aspermatogenesis. Exploration as a nodel for auto-allergic diseases.
Topics: Acid Phosphatase; Aminopeptidases; Animals; Antigens; Autoimmune Diseases; Cathepsins; Deoxyribonucl | 1972 |
[Use of sorbitol in the treatment of postoperative intestinal paralysis (clinico-experimental study)].
Topics: Adult; Aged; Animals; Disease Models, Animal; Electrophysiology; Gastrointestinal Motility; Humans; | 1971 |